Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year High – Here’s What Happened

by · The Cerbat Gem

Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report)’s stock price hit a new 52-week high on Monday . The stock traded as high as $5.54 and last traded at $5.4440, with a volume of 3382537 shares changing hands. The stock had previously closed at $5.05.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday. Robert W. Baird boosted their price target on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Thursday, October 2nd. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Citizens Jmp lifted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies has an average rating of “Moderate Buy” and a consensus price target of $10.42.

Check Out Our Latest Research Report on Taysha Gene Therapies

Taysha Gene Therapies Stock Performance

The company has a market cap of $1.49 billion, a price-to-earnings ratio of -16.52 and a beta of 1.06. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The firm has a fifty day simple moving average of $4.52 and a 200 day simple moving average of $3.38.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. On average, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 260,047 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the sale, the insider directly owned 1,006,439 shares in the company, valued at $4,539,039.89. This trade represents a 20.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 570,172 shares of company stock valued at $2,341,906. 3.78% of the stock is owned by corporate insiders.

Institutional Trading of Taysha Gene Therapies

Several institutional investors have recently modified their holdings of the company. ST Germain D J Co. Inc. increased its holdings in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after buying an additional 4,333 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $40,000. Marex Group plc acquired a new stake in Taysha Gene Therapies in the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the second quarter valued at $31,000. Finally, Allegheny Financial Group acquired a new position in Taysha Gene Therapies during the third quarter worth $49,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Stories